IASLC

@IASLC

The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer. #LCSM

Denver, CO

Joined July 2009

2KFollowing

20KFollowers

IASLC@IASLC · 13 h

What were the key takeaways from #ASCO25? In this episode of #LungCancerConsidered in Japanese, @MNagasaka hosts Dr. Yasushi Goto & @YukoO10942665 to discuss major ASCO data, including CheckMate 816, NEOADAURA & more. 🎧 bit.ly/ASCO25Japanese #LungCancer

IASLC's tweet image. What were the key takeaways from #ASCO25? In this episode of #LungCancerConsidered in Japanese, @MNagasaka hosts Dr. Yasushi Goto &amp; @YukoO10942665 to discuss major ASCO data, including CheckMate 816, NEOADAURA &amp; more.

🎧 bit.ly/ASCO25Japanese

#LungCancer

1.0K

IASLC@IASLC · Jul 25

Registration & abstracts for #NACLC25 are OPEN! Join us Dec 5–7, 2025, in Chicago. Submit abstracts by Sept 19! bit.ly/NACLC25 🎧 Hear from co‑chairs @kamarroneMD & @rarengan #LungCancerConsidered: what’s new & why you should attend. bit.ly/NACLC25Preview @ASCO…

IASLC's tweet image. Registration &amp; abstracts for #NACLC25 are OPEN! Join us Dec 5–7, 2025, in Chicago. Submit abstracts by Sept 19! bit.ly/NACLC25

🎧 Hear from co‑chairs @kamarroneMD &amp; @rarengan #LungCancerConsidered: what’s new &amp; why you should attend. bit.ly/NACLC25Preview

@ASCO…

3.0K

IASLC@IASLC · Jul 25

An expert IASLC multidisciplinary panel used a Delphi process to agree on 26 quality indicators to be considered in LCS program development and LCS public health practice. #lcsm #lungcancer Read now ➡️ bit.ly/46WUxD7

IASLC's tweet image. An expert IASLC multidisciplinary panel used a Delphi process to agree on 26 quality indicators to be considered in LCS program development and LCS public health practice. #lcsm #lungcancer

Read now ➡️ bit.ly/46WUxD7

976

IASLC@IASLC · Jul 24

🔬 Dr. @HwakeleeMD presented updated IMpower010 results highlighting the long-term benefits of adjuvant atezolizumab in resected NSCLC. 🔗 More in ILCN: bit.ly/4o6XZBn #LCSM

IASLC's tweet image. 🔬 Dr. @HwakeleeMD presented updated IMpower010 results highlighting the long-term benefits of adjuvant atezolizumab in resected NSCLC.

🔗 More in ILCN: bit.ly/4o6XZBn #LCSM

2.0K

IASLC@IASLC · Jul 20

Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy. In this episode of #LungCancerConsidered, @NarjustFlorezMD and @sands_jacob break down the data and clinical implications of this exciting development. 🎧…

IASLC's tweet image. Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR &amp; platinum therapy.

In this episode of #LungCancerConsidered, @NarjustFlorezMD and @sands_jacob break down the data and clinical implications of this exciting development.

🎧…

2.0K

IASLC@IASLC · Jul 19

Committee Spotlight: Dr. Tom E. Stinchcombe outlines the IASLC Multidisciplinary Clinical Science Committee's global initiatives and research goals. 🔗 Learn more: bit.ly/4m63DlC #LCSM

IASLC's tweet card. Dr. Tom Stinchcombe discusses how this new IASLC committee is aiming to define multidisciplinary care, improve global access, and support collaborative science.

1.0K

IASLC@IASLC · Jul 17

⏳Just 2 days left! Last chance to register for #WCLC2025 at discounted rates. Join the world’s leading lung cancer experts in Barcelona, September 6-9! 🔗 bit.ly/4nSE0X3 #IASLC #LungCancer #Oncology #CancerResearch #Barcelona2025 #MedicalConference

IASLC's tweet image. ⏳Just 2 days left!

Last chance to register for #WCLC2025 at discounted rates.

Join the world’s leading lung cancer experts in Barcelona, September 6-9!
🔗 bit.ly/4nSE0X3

#IASLC #LungCancer #Oncology #CancerResearch #Barcelona2025 #MedicalConference

1.0K

IASLC@IASLC · Jul 15

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, @StephenVLiu, @MariamAlex26 & Dr. James Chih-Hsin Yang break down the data and explore clinical impact. 🎧 bit.ly/FDAexon20

IASLC's tweet image. The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, @StephenVLiu, @MariamAlex26 &amp; Dr. James Chih-Hsin Yang break down the data and explore clinical impact.

🎧 bit.ly/FDAexon20

3.0K

IASLC@IASLC · Jul 11

🚨 There's still time to submit your abstract for #ACLC2025! 🗓️ New deadline: July 18 Submit your research and join us in Ho Chi Minh City, Vietnam, October 9-11. 🔗 bit.ly/44JZHzQ #IASLC #LungCancer #Oncology #CallForAbstracts #CancerResearch

IASLC's tweet image. 🚨 There's still time to submit your abstract for #ACLC2025!

🗓️ New deadline: July 18

Submit your research and join us in Ho Chi Minh City, Vietnam, October 9-11.

🔗 bit.ly/44JZHzQ

#IASLC #LungCancer #Oncology #CallForAbstracts #CancerResearch

2.0K

IASLC@IASLC · Jul 11

How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion with @HaradaGuilherme and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport

IASLC's tweet image. How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion with @HaradaGuilherme and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC.

🎧 Listen now: bit.ly/VTBport

2.0K

IASLC@IASLC · Jul 5

.@LAGurwitch highlights the financial burden US patients face accessing targeted therapies, which are often driven by pharmacy benefit practices. 🔗 Full article in #ILCN: bit.ly/4ltwTlK #LCSM #PatientAdvocacy #IASLC

IASLC's tweet card. Advocate and best-selling author Annabelle Gurwitch shines light on pharmacy benefit practices that cost patients thousands while increasing profits for insurance companies.

2.0K

IASLC@IASLC · Jul 2

.@charlesrudin shared promising DeLLphi-304 trial data on tarlatamab at #ASCO25. 🔗 Full highlights in ILCN: bit.ly/4leYUxC #LCSM

IASLC's tweet card. Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with...

1.0K

IASLC@IASLC · Jul 1

How should clinicians approach resectable EGFR-mutant #NSCLC? On the latest #LungCancerConsidered episode, @StephenVLiu moderates a case discussion with @collin_blakely and @susu_mail0513, covering evolving strategies and clinical decision-making. 🎧 bit.ly/VTBregfrnsclc

IASLC's tweet image. How should clinicians approach resectable EGFR-mutant #NSCLC? On the latest #LungCancerConsidered episode, @StephenVLiu moderates a case discussion with @collin_blakely and @susu_mail0513, covering evolving strategies and clinical decision-making.

🎧 bit.ly/VTBregfrnsclc

2.0K

IASLC@IASLC · Jun 30

🌍 Join the global lung cancer community at #WCLC25 in Barcelona, Sept 6–9! 🔬 Cutting-edge science, global networking & expert insights. 🎟️ Register now & save: wclc.iaslc.org #LungCancer #Oncology #IASLC #MedicalConference

IASLC's tweet image. 🌍 Join the global lung cancer community at #WCLC25 in Barcelona, Sept 6–9!
🔬 Cutting-edge science, global networking &amp; expert insights.
🎟️ Register now &amp; save: wclc.iaslc.org
#LungCancer #Oncology #IASLC #MedicalConference

4.0K

IASLC@IASLC · Jun 29

#ICYMI: VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv. 🔗 Read more in ILCN: bit.ly/46kWZDd #IASLC #ILCN

IASLC's tweet card. VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.

830

IASLC@IASLC · Jun 27

Drs. Rachael Murray and Emma O’Dowd offer insights into smoking cessation in lung cancer screening. 🔗 More details in ILCN: bit.ly/46fzL1d #IASLC #ILCN #lungcancerscreening

IASLC's tweet card. Drs. Rachael Murray and Emma O’Dowd say despite increasing evidence that cessation efforts within screening programs are effective, a lack of clear guidance means this opportunity is often missed.

1.0K

IASLC@IASLC · Jun 26

Datopotamab deruxtecan-dlnk receives accelerated FDA approval for treating EGFR-mutated non-small cell lung cancer. 📄 Full details ➡️ bit.ly/44fIz4B #FDAApproval #OncologyNews #NSCLC #AcceleratedApproval

IASLC's tweet card. On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.).

1.0K

IASLC@IASLC · Jun 26

The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, @StephenVLiu, @EnriquetaFelip & @nievamd discuss this approval & how to position taletrectinib among treatment options. 🎧 bit.ly/FDATaletrectin…

IASLC's tweet image. The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, @StephenVLiu, @EnriquetaFelip &amp; @nievamd discuss this approval &amp; how to position taletrectinib among treatment options.

🎧 bit.ly/FDATaletrectin…

2.0K

IASLC@IASLC · Jun 25

🌍 Clinicians & those with lived experience in thoracic cancer care: help improve tobacco dependency services. The AIRSPACE Study survey is now in English, Spanish, Japanese & Mandarin! 🕒 15–20 mins 🔒 🎁 Complete by July 2 to win #WCLC25 reg! 👉 bit.ly/IASLCAirspace…

IASLC's tweet image. 🌍 Clinicians &amp; those with lived experience in thoracic cancer care: help improve tobacco dependency services. The AIRSPACE Study survey is now in English, Spanish, Japanese &amp; Mandarin!

🕒 15–20 mins 🔒
🎁 Complete by July 2 to win #WCLC25 reg!
👉 bit.ly/IASLCAirspace…

1.0K

IASLC@IASLC · Jun 24

🌍 How is lung cancer managed around the world? Join us July 3 for a global tumor board tackling real case discussions from diagnosis to survivorship. Featuring experts: @rajatthawani, @TurgemanIlit, @cspramesh, @DrRoselleDG, @pablomunozsch & more! 🔗 bit.ly/43WgnFa

IASLC's tweet image. 🌍 How is lung cancer managed around the world?
Join us July 3 for a global tumor board tackling real case discussions from diagnosis to survivorship.

Featuring experts: @rajatthawani, @TurgemanIlit, @cspramesh, @DrRoselleDG, @pablomunozsch &amp; more!
🔗 bit.ly/43WgnFa

2.0K